NCT00565006

Brief Summary

This study will investigate the influence of MK0859 on ambulatory blood pressure, and how safe and tolerable MK0859 is on the subjects This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jul 2006

Shorter than P25 for phase_1

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2006

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

November 27, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 29, 2007

Completed
Last Updated

February 27, 2015

Status Verified

February 1, 2015

Enrollment Period

2 months

First QC Date

November 27, 2007

Last Update Submit

February 25, 2015

Conditions

Ambulatory Blood Pressure

Interventions

MK0859DRUG

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • You are between the ages of 45-75
  • You are a man or non-pregnant woman
  • You agree to not eat or drink fruit or fruit juices (orange, apple or grapefruit) for 2 weeks before starting study medication

You may not qualify if:

  • You have smoked or used other nicotine-containing products (chewing tobacco) within the last 6 months
  • You have used St. John's Wort or any products that include it within the last 2 weeks
  • You have used herbal, organic, dietary or nutritional remedies within the last 2 weeks
  • You have a history of drug allergies (anaphylaxis, angioedema)
  • You have taken an investigational drug in another clinical trial within the last 4 weeks
  • You have a history of cardiovascular disease including hypertension (high blood pressure)
  • You have a history of renal disease
  • You have a history of gall bladder disease or have had abnormal liver function tests
  • You have a history of drug or alcohol abuse
  • You drink more than 6 cups of caffeinated beverages a day (coffee, tea or cola)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007 Dec 8;370(9603):1907-14. doi: 10.1016/S0140-6736(07)61813-3.

    PMID: 18068514DERIVED

MeSH Terms

Interventions

anacetrapib

Study Officials

  • Medical Monitor

    Merck Sharp & Dohme LLC

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 27, 2007

First Posted

November 29, 2007

Study Start

July 1, 2006

Primary Completion

September 1, 2006

Study Completion

September 1, 2006

Last Updated

February 27, 2015

Record last verified: 2015-02